Dynamic immune signatures as biomarkers for irAEs

Jingwen Yang; Yamei Chen; Leng Han

doi:10.1016/j.trecan.2023.03.004

Dynamic immune signatures as biomarkers for irAEs

Trends Cancer. 2023 May;9(5):379-380. doi: 10.1016/j.trecan.2023.03.004. Epub 2023 Mar 21.

Authors

Jingwen Yang¹, Yamei Chen¹, Leng Han²

Affiliations

¹ Center for Epigenetics and Disease Prevention, Institute of Biosciences and Technology, Texas A&M University, Houston, TX, USA.
² Center for Epigenetics and Disease Prevention, Institute of Biosciences and Technology, Texas A&M University, Houston, TX, USA; Department of Translational Medical Sciences, College of Medicine, Texas A&M University, Houston, TX, USA. Electronic address: leng.han@tamu.edu.

PMID: 36941187
DOI: 10.1016/j.trecan.2023.03.004

Abstract

Identifying predictive biomarkers of immune-related adverse events (irAEs) is crucial to maximize the benefits for patients with cancer treated with immune checkpoint inhibitors (ICIs). In a recent study published in Med,Nuñez et al. utilized multi-omics approaches and identified blood immune signatures that have the potential to predict the development of autoimmune toxicity.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Biomarkers
Humans
Immune Checkpoint Inhibitors / therapeutic use
Immunotherapy / adverse effects
Neoplasms* / drug therapy
Neoplasms* / etiology

Substances

Biomarkers
Immune Checkpoint Inhibitors

Grants and funding

R01 CA262623/CA/NCI NIH HHS/United States